Citations

Clear

381 citation(s) found for "Gross, M".

Functional Impact of Transoral Surgery and Risk-Based Adjuvant Therapy in Human Papillomavirus–Associated Oropharyngeal Cancer: Swallowing Outcomes From ECOG-ACRIN E3311
Hutcheson, Katherine A. , Flamand, Yael , Manduchi, Beatrice , Quon, Harry , Weinstein, Gregory S., Mehra, Ranee , García, Joaquin J., Peterson, Christine B. , Barbon, Carly E. A. , Özer, Enver , Koch, Wayne M. , Civantos, Francisco , Thomas, Tom , Smith, Russel B., Gal, Thomas J. , Peterson, Christine , Flamand, Yael , Quon, Harry , García, Joaquin J., Lewin, Jan S. , Kim, Seungwon , Gross, Neil D , Bell, R. Bryan , Saba, Nabil F. , Holsinger, F. Christopher , Mehra, Saral , Ferris, Robert L. , Burtness, Barbara

Mayo Clinic

JCO Oncology Advances | November 17, 2025 | Volume: No volume available | Issue: 2 | Pages: No page available

10.1200/oa-25-00092 | PMID 41924493 Get It

PURPOSE The ECOG-ACRIN E3311 phase II trial demonstrated outstanding disease control (90.6% 54-month progression-free survival) after transoral surgery (TOS) with de-escalated, risk-based postoperative management in resectable human papillomavirus–associated oropharyngeal cancer. The goal of de-escalation was functional preservation. The objective of this work was to evaluate clinician-graded modified barium swallow (MBS) studies from E3311 over time and across arms for (1) aspiration and high-grade pharyngeal residue rates, (2) differences in swallow safety and efficiency, and (3) accuracy of site clinicians reporting against central MBS review. METHODS Eight hundred eighty-five MBS studies were performed on 314 patients from 50 of 59 sites at baseline, post-TOS, and 6 and 24 months postradiotherapy (RT). Swallow outcomes (aspiration, high-grade residue) were recorded by site clinicians. A subset of 414 MBS studies was centrally graded using penetration-aspiration scale scores and the Dynamic Imaging Grade of Swallowing Toxicity (DIGEST) scale. RESULTS Aspiration, residue, and dysphagia rates significantly increased from baseline to post-TOS ( P < .01) and then decreased modestly at 6 and 24 months. At 6 months, swallow outcomes favored the 50- versus 60-Gy arm, with significantly lower aspiration and high-grade dysphagia rates, but this difference was not maintained at 24 months. MBS results reported by site clinicians demonstrated substantial agreement with those assessed by the central laboratory (PABAK, 0.75-0.84; P < .01). CONCLUSION Swallowing worsened after TOS but improved by 6 and 24 months despite adjuvant therapy. De-escalated adjuvant RT at 50 Gy reduced acute aspiration. Site-reported MBS metrics strongly aligned with DIGEST, showing potential as an accessible metric in cooperative group settings.
Decentralized Biobanking to Empower Patient Engagement in Biospecimen Research: Operational Feasibility Case Study
Dewan, Ananya, Jesus, Vivian Altiery De, Budd, Eve , Sánchez, William , Kahn, Jeff, Macis, Mario , Gross, Marielle S. , Gross, M. , Dewan, Ananya, Kahn, Jeff, Miller, Robert C.

Mayo Clinic

Biopreservation and Biobanking | October 30, 2025 | Volume: 24 | Issue: 3 | Pages: 257-271

10.1177/19475535251384429 | PMID 41161689 Get It

Background: Biobanks often lack standard mechanisms to keep donors connected to their biospecimens, reflecting a broken feedback loop that compromises trust, engagement, and scientific progress. Decentralized biobanking empowers patients to track their donations throughout the research journey, supporting personalized feedback and research collaboration via a privacy-preserving blockchain network. This case study explores operational feasibility of implementing decentralized biobanking for a large breast cancer biobank at a US academic medical center. Methods: A mixed-methods case study of the groundwork, implementation, and stakeholder feedback for a real-world decentralized biobanking app pilot was conducted. Biobank members were recruited from February to April 2023. Operational feasibility was assessed via analysis of institutional stakeholder perspectives, pilot engagement, and de-bi app activity. Findings: Physicians and other biobank stakeholders surfaced challenges surrounding managing expectations, balancing empowerment with clinical and research workflows, and navigating power dynamics between patients, physicians, scientists, and leadership. A total of 1080 participants enrolled over 10 weeks, including nearly 10% of the biobank with about 4000 biospecimens. During the pilot, biobank enrollment increased 65% versus the prior year, and there were no biobank withdrawals during or within 1 year following the pilot ( p < 0.001 for both). The app, which facilitated biospecimen tracking and research engagement, was downloaded by 405 users. A total of 140 users tested the blockchain component, with 89% successfully claiming a nonfungible token representing their unique, immutable connection and access to donated biospecimens. Feedback was solicited to inform potential process improvements and risk assessments related to public relations, systems infrastructure, and ethical governance, illuminating next steps. Conclusions: We established operational feasibility for the first step toward decentralized biobanking, informed by requirements to manage expectations, workflows, and power dynamics. Our technical solution demonstrated robust participant engagement and compatibility with established biobanks, suggesting potential to build trust and align incentives and identifying next steps for communications, sustainability, and governance.
(010) UNVEILING THE IMPACT OF BODY MASS INDEX ON OVERALL OUTCOMES OF INFLATABLE PENILE PROSTHESIS PLACEMENT: INSIGHTS FROM AN INTERNATIONAL, MULTI-CENTER INVESTIGATION
Hammad, MAM, Gross, MS, Andrianne, Robert, Burnett, AL, Gross, Kelli, Hatzichristodoulou, G, Lentz, A, Modgil, Vaibhav , Perito, P, Hotaling, JM, Park, SH, Pearce, Ian , Sadeghi‐Nejad, Hossein , Sempels, Maxime, Suarez-Sarmiento, A, Renterghem, Katrien Van, Warner, J, Ziegelmann, Matthew , Hsieh, TC, Karthikeyan, Hridhay, Simhan, Jay , Yafi, FA, collaborators, on behalf of the PUMP (Prosthetic Urology Multi-institutional Partnership), Barham, DW, Hammad, Muhammed , Miller, Jake A. , Chawareb, Elia Abou , Amini, Erfan , Hatzichristodoulou, Georgios , Lentz, A, Osmonov, D, Suarez‐Sarmiento, Alfredo, Azad, Babak Kazemzadeh , Jenkins, Lawrence C. , Jones, James M. , collaborators, on behalf of the PUMP (Prosthetic Urology Multi-institutional Partnership), Barham, DW

Mayo Clinic

The Journal of Sexual Medicine | October 25, 2025 | Volume: 21 | Issue: Supplement_6 | Pages: No page available

10.1093/jsxmed/qdae161.010 Get It

Abstract Introduction Obesity, defined as an elevated Body Mass Index (BMI) &gt;30, is a prevalent public health concern with far-reaching implications for various medical procedures and outcomes. In the context of inflatable penile prosthesis placement (IPP), where patient well-being and surgical success are of paramount importance, the impact of obesity on postoperative and intraoperative complications warrants thorough investigation. Objective Our study aimed to investigate the impact of BMI on both postoperative and intraoperative complications in an international, multi-institutional cohort of patients who underwent IPP placement. Methods We performed a retrospective chart review of 4398 cases. These cases were divided into two distinct groups based on BMI: less than 30 (n = 2260) and greater than or equal to 30 (n = 2138). The study assessed various surgical factors as well as complications, including overall complications, corporal scarring, incontinence, intraoperative complications, proximal perforation, distal perforation, proximal crossover, distal crossover, and urethral injury. Results Our analysis revealed that there were no statistically significant differences in intraoperative or postoperative complications between the two BMI categories. Notably, proximal corporal measurement was significantly higher for &gt;30 BMI group (9.55 +/−2.18) compared to &lt;30 BMI group (9.14 +/−2.19), (p = &lt; 0.001). The incidence rates for overall complications (30.2% vs. 28.7%; p = 0.164), corporal scarring (18.2% vs. 16.7%; p = 0.36), incontinence (3.53% vs. 3.13%; p = 0.076), intraoperative complications (1.94% vs. 1.68%; p = 0.253), and specific complications all exhibited no significant differences. Similarly, post-operative complications, including both non- infectious (6.99% vs. 6.22%; p = 0.215) and infectious (2.61% vs. 1.87%; p = 0.165) complications, did not significantly vary between BMI categories. Conclusions Our findings indicate that BMI does not exert a statistically significant influence on postoperative and intraoperative complications in the context of high-volume prosthetic urology. In the absence of any other differences between patients of differing BMIs, surgeons may need to be mindful of pump tubing length concerns in obese patients. Disclosure Any of the authors act as a consultant, employee or shareholder of an industry for: Coloplast, Clarus Therapeutics, Antares Pharma, Acerus.
Cost-Effectiveness and Evidence Gaps Surrounding PSMA-PET for Recurrent Prostate Cancer Evaluation
Long, Jessica B., Sprenkle, Preston C. , Kim, Isaac Yi , Saperstein, Lawrence, Rabil, Maximilian , Ghaffar, Umar , Karnes, R. Jeffrey , Ma, Xiaomei , Gross, Cary P. , Leapman, Michael S., Kunst, Natalia , Wang, Shi‐Yi

Mayo Clinic

JAMA Network Open | October 24, 2025 | Volume: 8 | Issue: 10 | Pages: e2539250

10.1001/jamanetworkopen.2025.39250 | PMID 41134573 Get It

Importance Prostate-specific membrane antigen positron emission tomography (PSMA-PET), a form of molecular imaging, increases detection of advanced and metastatic prostate cancer, but its potential to increase treatment costs due to increased detection is poorly defined. Objective To estimate lifetime health and cost outcomes and evaluate the cost-effectiveness associated with implementing PSMA-PET in the clinical evaluation of a patient with a biochemical recurrence (BCR) of prostate cancer, with evaluation of sources of uncertainty in the underlying evidence and assessment of the need and focus of additional data collection. Design, Setting, and Participants This economic evaluation developed a decision-analytic model consisting of a decision tree and a Markov model informed by published literature and a study of patients with BCR prostate cancer undergoing PSMA-PET after definitive surgery or radiation therapy at 2 high-volume US academic centers. The analysis was performed between August 1, 2024, and May 1, 2025. Interventions Patients underwent (1) PSMA-PET, (2) PSMA-PET imaging as a reflex test if computed tomography plus bone scan (CTBS) was negative or equivocal (CTBS + PSMA-PET), and (3) CTBS alone. Main Outcomes and Measures Lifetime quality-adjusted life-years (QALYs) and costs, incremental cost-effectiveness ratio (ICER), and value of information estimates were assessed, with 95% uncertainty intervals (UIs). We assumed a willingness-to-pay threshold of $150 000 per QALY. Results The model simulated 1000 patients with BCR (median age, 66 years) and estimated that up-front PSMA-PET is expected to have the highest mean QALYs (7.12 QALYs [95% UI, 6.71-7.51 QALYs]) compared with 6.55 QALYs (95% UI, 6.08-7.03 QALYs) for CTBS; it was also estimated to have higher mean costs ($451 000 [95% UI, $336 000-$577 000]) compared with $351 000 (95% UI, $263 000-$455 000]) for CTBS; consequently, PSMA-PET had mean increments of $99 000 (95% UI, $55 000-153,000) in costs and 0.58 QALYs (95% UI, 0.35-0.82 QALYs) compared with CTBS, leading to an ICER of $172 000 per QALY, which exceeded the assumed $150 000/QALY willingness-to-pay threshold. In patients with lower prostate-specific antigen levels (&amp;lt;2 ng/mL), PSMA had mean increments of $61 000 (95% UI, $21 000-$104 000) in costs and 0.54 QALYs (95% UI, 0.34-0.77 QALYs) compared with CTBS, leading to an ICER of $113 000/QALY, suggesting it had the potential to be cost-effective. Because of high decisional uncertainty, additional information regarding outcomes and diagnostic characteristics may be associated with reduced uncertainty and a gain of 15 747 QALYs. Conclusions and Relevance This study found that PSMA-PET may be associated with improved disease detection but may not be cost-effective due to high treatment costs offsetting moderate improvements in QALYs. Further research is needed to identify patient subsets and clinical scenarios in which molecular imaging provides the greatest value.
Vitamin D Endocrine System and Calcium and Phosphorus Homeostasis
Gross, Myron D., Kumar, Rajiv

Mayo Clinic

Comprehensive Physiology | October 23, 2025 | Volume: 1991 | Issue: 6S25 | Pages: 1817-1839

10.1002/j.2040-4603.1991.tb01595.x Get It

Abstract The sections in this article are: Physiological Effects of Vitamin D and its Active Metabolites on Calcium and Phosphorus Homeostasis Sources of Vitamin D Transport of Vitamin D and its Metabolites in Plasma Metabolism of Vitamin D 3 to 25‐Hydroxyvitamin D 3 Metabolism of 25‐Hydroxyvitamin D 3 Regulation of the 25‐Hydroxyvitamin D 3 –1α‐Hydroxylase Enzyme Parathyroid Hormone Phosphorus Concentrations Calcium: Direct Effects 1,25‐Dihydroxyvitamin D 3 Calcitonin Hydrogen Ion Sex Steroids Glucocorticoids Pituitary Hormones Thyroid Hormone Pregnancy Catabolism of 1,25‐Dihydroxyvitamin D 3 Physiological Adaptations that Occur in Response to Changes in Serum Calcium and Phosphate Concentrations Hypocalcemia and Hypercalcemia Hypophosphatemia and Hyperphosphatemia Pathophysiology and Physiology of the 1,25‐Dihydroxyvitamin D 3 System Mechanisms of Action of 1,25‐Dihydroxyvitamin D 3 1,25‐Dihydroxyvitamin D 3 in the Intestine Processes in the Cell That Are Mediated by 1,25‐Dihydroxyvitamin D 3 Intestinal Brush Border Events Induced by 1,25‐Dihydroxyvitamin D 3 Events at the Contraluminal Border Effects of 1,25‐Dihydroxyvitamin D 3 on the Intestinal Cell 1,25‐Dihydroxyvitamin D 3 in the Kidney
What Is Clinical Anatomy?—A Consensus Statement From the American Association of Clinical Anatomists
Rajaram‐Gilkes, Mathangi, Chaiyamoon, Arada , Ezra, David , Raoof, Ameed , Rae, Guenevere , Mtui, Estomih P., Detton, Alan J., Anand, Mahindra , Raeburn, Kazzara , Kim, Hee‐Jin , Sekhar, Laligam N., Watanabe, Koichi , D’Antoni, Anthony V. , Loukas, Marios , Spinner, Robert J. , Tubbs, R. Shane, Iwanaga, Joe , Ezra, David , Rae, Guenevere , Kim, Hee-Jin , Watanabe, Koichi , Antoni, Anthony D' , Loukas, Marios , Spinner, Robert J , Adds, Philip , Iwanaga, Joe , Bubb, Kathleen , Rajaram-Gilkes, Mathangi, Noël, Geoffroy P. J. C. , Hur, Mi-Sun , Sekhar, Laligam N. , Tabira, Yoko , Khalil, Mohammed K. , Adds, Philip J.

Mayo Clinic

Clinical Anatomy | October 21, 2025 | Volume: 39 | Issue: 1 | Pages: 72-76

10.1002/ca.70040 | PMID 41117176 Get It

ABSTRACT At the 42nd Annual Meeting of the American Association of Clinical Anatomists (AACA) in Bellevue, Washington, June 2025, two inaugural events—the Clinical Anatomy Fireside Chat (CAFC) and the Clinical Anatomy Symposium: Head and Neck 2025 (CAS)—fostered rich dialogue on the evolving role and operational definition of clinical anatomy. Experts from various clinical and anatomical disciplines explored the meaning of clinical anatomy, highlighting the absence of a universal definition despite its frequent use in education and research. Through these interdisciplinary discussions, a consensus emerged: clinical anatomy is not defined solely by the possession of clinical credentials but by the integration of anatomical knowledge and clinical relevance, achieved most effectively through collaboration. Clinical anatomy education and research require different depths of clinical knowledge depending on the audience and objective, and meaningful collaboration can bridge gaps in expertise. The symposium further illustrated that high‐quality clinical anatomy emerges from mutual respect and reciprocal insight between clinicians and anatomists. This article presents a consensus statement developed by AACA representatives and invited speakers, affirming that collaboration is not only foundational to the practice of clinical anatomy but also fundamental to its definition. These conclusions aim to guide future educational models, research strategies, and interdisciplinary partnerships in the field of clinical anatomy.
Incarceration and Quality of Cancer Care
Aminawung, Jenerius A. , Weinstein, Jason , Puglisi, Lisa B. , Mehta, Rajni , Lin, Hsiu‐Ju , Wang, Emily A. , Gross, Cary P. , Oladeru, Oluwadamilola T. , Richman, Ilana B.

Mayo Clinic

JAMA Network Open | October 14, 2025 | Volume: 8 | Issue: 10 | Pages: e2537400

10.1001/jamanetworkopen.2025.37400 | PMID 41085984 Get It

ImportanceAlthough incarceration is associated with worse cancer outcomes, little is known about quality of cancer care among people with a history of incarceration.ObjectiveTo describe quality of cancer care among those diagnosed with cancer during or immediately after incarceration.Design, Setting, and ParticipantsThis longitudinal cohort study used Connecticut Tumor Registry data linked to Department of Correction rosters from 2005 through 2016. Patients diagnosed with cancer while incarcerated were matched to those diagnosed within 12 months after incarceration and to those with no history of incarceration. Analysis was performed between March 2024 and January 2025.ExposuresIncarceration status at time of cancer diagnosis.Main Outcomes and MeasuresThe main outcomes were treatment initiation within 60 days and receipt of recommended pretreatment and therapeutic care, ascertained from medical records and tumor registries. Logistic regression was used to evaluate odds of treatment initiation by 60 days. The proportion of recommended elements of pretreatment and therapeutic care received was calculated, and group differences were assessed using χ2 tests.ResultsThe sample included 690 individuals (233 diagnosed during incarceration, 221 diagnosed within 12 months after incarceration, and 236 with no incarceration history). The mean (SD) age was 49.7 (12.1) years, and 611 (88.6%) were male. Compared with those with no history of incarceration, those diagnosed with cancer during incarceration were less likely to initiate treatment within 60 days (169 of 209 [80.9%] vs 131 of 189 [69.3%]; OR, 0.49 [95% CI, 0.31-0.79]). Initiation of treatment within 60 days was not statistically different for those diagnosed after incarceration vs those with no history of incarceration (144 of 187 [77.0%]; OR, 0.81 [95% CI, 0.49-1.34]). Those diagnosed with local and regional cancers during incarceration received 49.2% of recommended treatment-related care (31 of 63 measures), while those diagnosed after incarceration received 45.3% (34 of 75 measures), compared with 66.7% (36 of 54 measures) among those with no history of incarceration (P &amp;lt; .001). People diagnosed with local and regional cancers during incarceration received 80.6% of recommended pretreatment evaluation (54 of 67 measures), and those diagnosed after received 96.8% (59 of 68 measures), compared with 78.1% (50 of 64 measures) among those with no history of incarceration (P = .01).Conclusions and RelevanceIn this cohort study of people with a history of incarceration, incarceration was associated with lower likelihood of receiving timely, high-quality cancer treatment. Along with other published literature, this work suggests that gaps in quality of care may contribute to observed disparities in outcomes.
A survey to assess practice patterns among clinicians administering collagenase Clostridium histolyticum for Peyronie’s disease
Parikh, Niki , Sischka, Michael, Gross, Martin , Yafi, Faysal A. , Ziegelmann, M., Vasdev, Ranveer , Kohler, Tobias S

Mayo Clinic

The Journal of Sexual Medicine | October 3, 2025 | Volume: 23 | Issue: 1 | Pages: No page available

10.1093/jsxmed/qdaf300 | PMID 41182293 Get It

PRRX1-rearranged Fibroblastic Tumors
Torres‐Mora, Jorge , Thangaiah, Judith Jebastin, Oliveira, André M. , Malik, Faizan , Din, Nasir Ud , Hassan, Usman , Maqbool, Hina , Caragea, Mara, Schubart, Christian, Grundtmann, Bo, Melchior, Linea Cecilie , Talman, Maj‐Lis, Cheah, Alison L., Thway, Khin , Fisher, Cyril , Torres-Mora, Jorge, Oliveira, Andre, Dehner, Carina , Michal, Michael , Obeidin, Farres , Lee, Cheng‐Han , Schubart, Christian, Agaimy, Abbas , Gross, John , Antonescu, Cristina R. , Linos, Konstantinos

Mayo Clinic

American Journal of Surgical Pathology | October 2, 2025 | Volume: 50 | Issue: 1 | Pages: 31-40

10.1097/pas.0000000000002472 | PMID 41036703 Get It

With the first series of PRRX1 -rearranged tumors published in 2019, the spectrum of these so-called fibroblastic tumors has been expanded. Since then, several smaller case series have been published; however, our understanding of them continues to be quite limited given their rarity. We herein studied 18 additional cases, the largest series to date. Eighteen tumors present in 9 male, 8 female, and 1 nonbinary patient with a median age of 35 years (range: 11 to 70 y) and involved the neck (5), the chest region (4), thigh (3), back (1), shoulder (1), forehead (1), lower leg (1), axilla (1), and the parapharyngeal region (1). Clinical follow-up (9/18 tumors; 50%; median: 10 mo; range: 4 to 40 mo) showed consistent indolent behavior without local recurrences or distant metastases. On morphology, these tumors were characterized by well-circumscription and distinctive peripheral crescent-shaped vessels. They were composed of uniform spindle and round cells growing in short fascicles within often densely hyalinized collagen lacking significant mitotic activity, necrosis, or cytologic atypia. Immunohistochemically, about half of the tested tumors expressed focal to rarely diffuse S100 with occasional co-expression of SOX10. Interestingly, almost half of the tested cases also showed complete loss of RB expression. All but 1 tumor harbored a PRRX1::NCOA1 fusion, while 1 case harbored a novel PRRX1::EP300 fusion. We herein provide additional data on these exceptionally uncommon tumors, expand their molecular spectrum, and compare them to their close morphologic mimics to aid in accurate diagnosis and avoid confusion with potentially more aggressive neoplasms.